NCT05911217 - A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Pancreatic Cancer

Interventions

DRUG

CT041 autologous CAR T-cell injection

Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion

Trial Locations (8)

RECRUITING

Ruijin Hospital, affiliated to Shanghai Jiaotong University, school of medicine, Shanghai

RECRUITING

Fudan University Shanghai Cancer Hospital, Shanghai

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Union Hospital, Tongji Medical College, Hua zhong University of Science and Technology, Wuhan

RECRUITING

Hunan Provincial People's Hospital, Changsha

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xian

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou